The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer

被引:94
|
作者
Afshar-Oromieh, Ali [1 ,2 ]
Sattler, Lars Peter [1 ]
Mier, Walter [1 ]
Hadaschik, Boris A. [3 ]
Debus, Juergen [4 ]
Holland-Letz, Tim [5 ]
Kopka, Klaus [6 ]
Haberkorn, Uwe [1 ,2 ]
机构
[1] Heidelberg Univ Hosp, Dept Nucl Med, Heidelberg, Germany
[2] German Canc Res Ctr, Clin Cooperat Unit Nucl Med, Heidelberg, Germany
[3] Heidelberg Univ Hosp, Dept Urol, Heidelberg, Germany
[4] Heidelberg Univ Hosp, Dept Radiat Oncol & Therapy, Heidelberg, Germany
[5] German Canc Res Ctr, Dept Biostat, Heidelberg, Germany
[6] German Canc Res Ctr, Div Radiopharmaceut Chem, Heidelberg, Germany
关键词
prostate cancer; PET/CT; positron emission tomography; PSMA; prostate-specific membrane antigen; tumor detection; GA-68-LABELED PSMA LIGAND; RADIATION-DOSIMETRY; MEMBRANE ANTIGEN; BIOCHEMICAL RECURRENCE; METASTASES;
D O I
10.2967/jnumed.116.183483
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Although PET/CT with Ga-68-PSMA-11 in the diagnosis of prostate cancer (PCa) is routinely performed at 1 h after injection, later scans may be beneficial because most lesions present with higher uptake and contrast. This evaluation aimed to investigate the clinical impact of additional late Ga-68-PSMA-11 PET/CT. Methods: Between 2011 and 2016, 112 patients with PCa who underwent early (at 1 h after injection) and late (at 3 h after injection) Ga-68-PSMA-11 PET/CT scans were retrospectively evaluated. The late scans were conducted to clarify unclear findings in early scans or to increase the probability of tumor detection in the case of negative early scans. All patients were asked to drink 1 L of water between early and late scans. In addition, 20 patients received 20 mg of furosemide before late scans. Tumor detection and radioactivity concentration within the urinary bladder were analyzed in both scans. The SUVmax and contrast of 149 tumor lesions were measured in 69 patients with pathologic findings. Results: Overall, 134 lesions characteristic for PCa in 57 patients clearly presented at 1 h after injection and 147 lesions in 68 patients at 3 h after injection. Forty-three patients showed no pathologic findings. Eight patients (7.1%) showed 1 unclear finding in early scans, which could be clarified as characteristic for PCa at 3 h after injection. Four patients (3.6%) presented with 1 lesion characteristic for PCa at 3 h after injection only. Twelve patients (10.7%) presented with 12 possible PCa lesions at 1 h after injection, which, however, could not be confirmed as PCa in late scans. Two patients presented with 1 lesion characteristic for PCa at 1 h after injection, which became invisible at 3 h after injection because of low contrast. At 3 h after injection, 62.4% of the lesions demonstrated a higher SUV. and 65.1 % a higher contrast than at 1 h after injection. Patients with furosemide presented with lower SUV and radioactivity concentration within the urinary bladder. Conclusion: 68Ga-PSMA-11 PET/CT at 3 h after injection showed most lesions characteristic for PCa with a higher uptake and contrast. In addition, the radioactivity signal within the urinary bladder was lower at 3 h after injection, especially when furosemide was applied. Consequently, scans at 3 h after injection detected more tumor lesions than at 1 h after injection.
引用
收藏
页码:750 / 755
页数:6
相关论文
共 50 条
  • [1] The clinical impact of additional late PET/CT-imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of recurrent prostate cancer
    Afshar-Oromieh, A.
    Sattler, L.
    Kratochwil, C.
    Giesel, F.
    Kopka, K.
    Haberkorn, U.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S166 - S166
  • [2] Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
    Ali Afshar-Oromieh
    Tim Holland-Letz
    Frederik L. Giesel
    Clemens Kratochwil
    Walter Mier
    Sabine Haufe
    Nils Debus
    Matthias Eder
    Michael Eisenhut
    Martin Schäfer
    Oliver Neels
    Markus Hohenfellner
    Klaus Kopka
    Hans-Ulrich Kauczor
    Jürgen Debus
    Uwe Haberkorn
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1258 - 1268
  • [3] Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
    Afshar-Oromieh, Ali
    Holland-Letz, Tim
    Giesel, Frederik L.
    Kratochwil, Clemens
    Mier, Walter
    Haufe, Sabine
    Debus, Nils
    Eder, Matthias
    Eisenhut, Michael
    Schaefer, Martin
    Neels, Oliver
    Hohenfellner, Markus
    Kopka, Klaus
    Kauczor, Hans-Ulrich
    Debus, Juergen
    Haberkorn, Uwe
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (08) : 1258 - 1268
  • [4] Impact of Ga-68 HBED-CC PSMA PET/CT on therapeutic management of patients with prostate cancer
    Schreiter, Vera
    Schreiter, Nils
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [5] The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of prostate cancer
    Akdemir, E.
    Tuncel, M.
    Tuncali, M. C.
    Bilen, C. Y.
    Akyol, F.
    Baydar, D.
    Ozen, H.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S679 - S679
  • [6] Erratum to: Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
    Ali Afshar-Oromieh
    Tim Holland-Letz
    Frederik L. Giesel
    Clemens Kratochwil
    Walter Mier
    Sabine Haufe
    Nils Debus
    Matthias Eder
    Michael Eisenhut
    Martin Schäfer
    Oliver Neels
    Markus Hohenfellner
    Klaus Kopka
    Hans-Ulrich Kauczor
    Jürgen Debus
    Uwe Haberkorn
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1781 - 1781
  • [7] 68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer
    Elif Neslihan Akdemir
    Murat Tuncel
    Fadıl Akyol
    Cenk Yucel Bilen
    Dilek Ertoy Baydar
    Erdem Karabulut
    Haluk Ozen
    Meltem Caglar
    [J]. World Journal of Urology, 2019, 37 : 813 - 821
  • [8] The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
    Afshar-Oromieh, Ali
    Avtzi, Eleni
    Giesel, Frederik L.
    Holland-Letz, Tim
    Linhart, Heinz G.
    Eder, Matthias
    Eisenhut, Michael
    Boxler, Silvan
    Hadaschik, Boris A.
    Kratochwil, Clemens
    Weichert, Wilko
    Kopka, Klaus
    Debus, Juergen
    Haberkorn, Uwe
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) : 197 - 209
  • [9] 68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer
    Akdemir, Elif Neslihan
    Tuncel, Murat
    Akyol, Fadil
    Bilen, Cenk Yucel
    Baydar, Dilek Ertoy
    Karabulut, Erdem
    Ozen, Haluk
    Caglar, Meltem
    [J]. WORLD JOURNAL OF UROLOGY, 2019, 37 (05) : 813 - 821
  • [10] The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
    Ali Afshar-Oromieh
    Eleni Avtzi
    Frederik L. Giesel
    Tim Holland-Letz
    Heinz G. Linhart
    Matthias Eder
    Michael Eisenhut
    Silvan Boxler
    Boris A. Hadaschik
    Clemens Kratochwil
    Wilko Weichert
    Klaus Kopka
    Jürgen Debus
    Uwe Haberkorn
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 197 - 209